ARVINAS, INC. (ARVN) research
ARVINAS, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $7.41
- As of
ARVINAS, INC. (ARVN): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
As of . Source: SEC EDGAR filings for ARVN. Method and limitations.
Share the ARVN intelligence card
See the full ARVN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ARVN on one page. Preview it with sample data, then open it live with a free account.
Preview the ARVN dossierActive signals for ARVN
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 68% of ARVN (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1782% to ARVN (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 784.0%, EPS $2.58 vs $-0.3772 estimate
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 90% of ARVN (2026Q1)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 54% of ARVN (2026Q1)
FREE, NO ACCOUNT
Every signal on ARVN, as it fires
You are seeing 5 of 9 signals recorded on ARVN since 2026-06-21.
The five above landed across 3 days. The other 4 were recorded on 1 other days. 5 of the 9 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARVN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 04335A105 · 2026Q2 | $29M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 04335A105 · 2026Q2 | $21.4M | 0.02% | , |
| CITADEL ADVISORS LLCCUSIP 04335A105 · 2026Q2 | $5.2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 04335A105 · 2026Q2 | $4.8M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 04335A105 · 2026Q2 | $1.8M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 04335A105 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARVN
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ARVN against its peers
ARVN's operating margin of -45.1% ranks in the 81st percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ARVN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 263M USD | 2.6M USD | 97 | 16 |
| Operating margin | -45.1% | -734.3% | 81 | 12 |
| Net margin | -30.8% | -887.0% | 81 | 12 |
| Return on equity | -18.6% | -50.5% | 80 | 21 |
Peers (22): RGNX, CTNM, AUTL, OVID, PBYI, ASMB, ENTX, EPRX, OCS, MNPR, CBIO, NGNE, DMAC, TECX, ALT, PRTA, INDP, PRME, CAPR, YDES, VALN, ALLO. Left out: DRUG (period gap), RLFTY (no annual filing), AGMB (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ARVN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ARVN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ARVNand get the insider, 13F, options, and confluence read in one view.